Methods for treating gastrointestinal motility dysfunction using optically pure (+) cisapride
US5955478A · kind A · utility
10Cited by
5References
20Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 21, 1996 |
| Grant date | Sep 21, 1999 |
| Priority date | — |
| Expiry date | Nov 21, 2016 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P1/14
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods are disclosed utilizing the optically pure (+) isomer of cisapride. The optically pure (+) isomer of cisapride is useful for the treatment of dyspepsia and such other conditions as may be related to the activity of (+) cisapride as a prokinetic agent, such as gastroparesis, constipation, post-operative operative ileus, and intestinal pseudo-obstruction, without the concomitant liability of adverse effects associated with the racemic mixture of cisapride. The (+) isomer of cisapride also exhibits longer duration of action than does racemic cisapride and is useful for treatment of disorders of the central nervous system.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.